Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | EO4010 |
| Trade Name | |
| Synonyms | EO-4010|EO 4010 |
| Drug Descriptions |
EO4010 is a cancer peptide vaccine composed of bacterial-derived peptides that are homologous to tumor-associated antigens (TAA), which potentially induces an anti-tumor immune response (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C192811 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| EO4010 | EO4010 | 0 | 1 |
| EO4010 + Nivolumab | EO4010 Nivolumab | 0 | 1 |